Saturday, 7 January 2017

#ThinkSpeak & #CharcotProject: what I love about science is that you are always learning

Teriflunomide the dark horse of MS is getting more attention. #ThinkSpeak #CharcotProject #MSBlog

I am always learning. Two things happened to me last year that have me take two steps back and say: 'Wow, I didn't know that, how interesting, could it explain these observations, could the drug be working this way or that way, can we test this and that hypothesis, how soon can we start, ....'

At ECTRIMS I met a very bright group of basic scientists from Sanofi-Genzyme who simply made me aware of the published data on the anti-viral effects of teriflunomide. In parallel, the charming and very collaborative neurologist Dr Keith Edwards, from Albany New York, came to visit our centre. During his stay he explained to me that the reason why he was doing the natalizumab to teriflunomide switch study was because of teriflunomide's anti-viral activity against BK virus. BK virus is the sister virus to the JC virus and if teriflunomide was effective against BK virus it should also be effective against JCV. The hypothesis is that teriflunomide may work against JCV and hence be able to prevent, and possibly treat, PML. Independently, of the Sanofi-Genzyme scientists, Dr Edwards had discovered this whole parallel universe of data on the anti-viral properties of leflunomide (teriflunomide's pro-drug) and teriflunomide. 


Dr Keith Edwards
Multiple Sclerosis Center Of Northeastern New York

Independent of these events I have been receiving anecdotal reports from my colleagues in North America, both the USA and Canada, of how well their patients are doing on teriflunomide long-term. They are all saying that in real-life teriflunomide is performing much better than what you would expect from the pivotal trials. Why? In addition to this, teriflunomide is the only DMT that works significantly better second, or third, line than it does first-line (see figure below). Why is teriflunomide the outlier amongst the DMTs? Could all these observations be linked to teriflunomide's mode of action as an anti-viral agent? This is a possibility and needs to be explored. Therefore Professor Julian Gold and I are putting together a proposal under the Charcot Project banner to explore the anti-viral, in this case anti-EBV, effects of teriflunomide. In parallel we propose looking at its impact of teriflunomide on JCV in pwMS. I sincerely hope you the MS community will be as supportive of this project as you have been about our other viral hypotheses. The difference with teriflunomide, compared to other anti-viral drugs, is that we don't have to assess whether or not it is effective as a DMT in MS as it is already a licensed drug. All we have to do is demonstrate its anti-viral effect and then try and correlate this with its efficacy. I hope you are as excited about these events as we are. 




Josephson et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation. 2006 Mar 15;81(5):704-10.


BACKGROUND: Polyoma BK virus produces an aggressively destructive nephropathy in approximately 3% to 8% of renal allografts, is associated with graft loss within one year in 35% to 67% of those infected and there is no therapy of proven efficacy. Leflunomide is an immune suppressive drug with anti viral activity in vitro and in animals.

METHODS: We treated twenty-six patients with biopsy proven NK virus nephropathy (BKN) with either leflunomide alone (n=17) or leflunomide plus a course of cidofovir (n=9) and followed them for six to forty months. Leflunomide was dosed to a targeted blood level of active metabolite, A77 1726, of 50 microg/ml to 100 microg/ml (150 microM to 300 microM). Response to treatment was gauged by serial determinations of viral load in blood and urine (PCR), serum creatinine, and repeat allograft biopsy.

RESULTS: In the 22 patients consistently sustaining the targeted blood levels of active drug, blood and urine viral load levels uniformly decreased over time (P<.001). Mean serum creatinine levels stabilized over the first six months of treatment, and with 12 months or more of follow-up in 16 patients the mean serum creatinine has not changed significantly from base line. Four patients who did not consistently have blood levels of active drug (A77 1726) above 40 microg/ml did not clear the virus until these levels were attained or cidofovir was added.

CONCLUSIONS: Leflunomide inhibits Polyoma virus replication in vitro and closely monitored leflunomide therapy with specifically targeted blood levels appears to be a safe and effective treatment for Polyoma BK nephropathy.

Morita et al. Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: A case report and literature review. J Clin Virol. 2016 Sep;82:133-8. doi: 10.1016/j.jcv.2016.07.015.

Ganciclovir-resistant cytomegalovirus infection is sometimes life-threatening for organ transplant recipients. Foscarnet is an alternative, although it may potentially worsen the preexistent impaired renal function. Here we report the case of a successful low-dose leflunomidetreatment in a kidney transplant recipient with very high viral replication, who underwent kidney transplantation 10 years before. Administering 10mg leflunomide daily for 5 months without a loading dose completely cleared the ganciclovir-resistant cytomegalovirus strains.


CoI: multiple

15 comments:

  1. Where's the evidence ProfG, otherwise its hearsay, surely Pharma have the data

    ReplyDelete
  2. So switching to teri from fingo or dmf for people with low lymphocytes an option? Has there never been a case of PML seen with teri? What about other infections?

    ReplyDelete
  3. Can't say that I understand everything but my understanding is that you now have something that could treat and prevent PML. Amazing. Go for it

    ReplyDelete
    Replies
    1. Hold your horse we have to see that aubagio can kill JC virus first. Aubagio is a proliferation killer and so kills stuff making DNA, maybe it works the same with viruses but it may be relative and not be an irradicator so lets see the data before we get too excited.

      Also what was the test because viruses infect cells, biologists often use cell lines to test stuff and these cell lines are often tumours that are dividing all the time, stop cell dividing and you may bugger the machinery that the virus uses to replicate itself.

      Beta interferon is an anti-viral and it does just that and so stops proliferation of cells however this is not the wonder cure of MS. There must be enough data collected to see the long term impact of teri, let's see this.

      Delete
  4. Teriflunomide is Aubagio isn't it?

    I had Aubagio and my lymphos got very low so I stopped.

    Afterwards I got a huge rebound (6 new lesions).

    I didn't feel any positive effects of Aubagio (had it for 18 months) and got new lesions whilst on it.

    Definately NOT a wonder.

    ReplyDelete
    Replies
    1. Sorry to hear your experience was not good.

      However, getting new lesions on a drug does not mean necessarily mean that it does not work, you may have had many more lesions without the drug and that you had relapse after stopping suggests it was keeping something in check.

      If we had a biomarker to show efficacy within the individual then we could see whats good or not in each individual so we could switch if necessary or retreat.

      I remember being at ECTRIMS and looking through the aubagio posters and thinking some of the effects were more than I expected for a low efficacy drug, but if pharma does not publish half the stuff it presents at ECTRIMS how can we evaluate a few seconds, view of one of hundreds of posters and being able to read and digest.


      Delete
    2. Anon 10.29 that doesn't sound so good. Have you been able to start any other DMT?

      Delete
    3. No, Judy, unfortunately I wasn't. I had been on Tecfidera prior to Aubagio but due to side-effects had to stop both.

      I am too scared to try Alem because I have psoriasis and that could flame up the RA.

      Maybe Rituximab but from what I read of the RA community it is no wonder drug either.

      Delete
  5. Is there a funding site for this effort?

    ReplyDelete
  6. I've lost institutional access to web of science.

    What's the literature say about the antiviral effect in culture? Specific to all, or certain types of DNA virus? What about RNA viruses?

    What kind of titre difference is there in culture? What about in mice?

    ReplyDelete
    Replies
    1. Your local public library may offer free access to web of science but this can only be accessed at the library. It's a scheme for the public and called Access to Research.

      Delete
  7. I liked it. I've heard of a pwMS that says strangely not to catch the flu anymore.
    She says she doen't remember when it was the last time she had a virus, she has been with Teriflunomide for almost 2 years.

    Anecdotal, but she reports it.
    I already in Copaxone and i'm having a very easy catch the flu.
    I'm only afraid of Teriflunomide in the liver.

    Would you have a crowdfounding like the one that went to check if raltegravir would act the EBV account?

    ReplyDelete
  8. Apparently Alpha-lipoic acid has antiviral properties too.

    ReplyDelete
    Replies
    1. This is one of the compounds that does everything, good evidence is needed to support claims

      Delete
  9. Sounds good - interesting hypothesis. When is this going to start? Do you need another crowdfunding initiative to get things going?

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.